Case Report: A Novel De Novo Missense Mutation of the GRIA2 Gene in a Chinese Case of Neurodevelopmental Disorder With Language Impairment

Bingbo Zhou1, Chuan Zhang1, Lei Zheng1, Zhiqiang Wang2, Xue Chen1, Xuan Feng1, Qinghua Zhang1, Shengjiu Hao1, Liwan Wei3, Weiyue Gu3 and Ling Hui1*

1Center for Medical Genetics, Gansu Provincial Clinical Research Center for Birth Defects and Rare Diseases, Gansu Provincial Maternity and Child Health Hospital, Lanzhou, China, 2Center for Men’s Health, Gansu Provincial Maternity and Child Health Hospital, Lanzhou, China, 3Chigene (Beijing) Translational Medical Research Center, Beijing, China

Introduction: Neurodevelopmental disorders with language impairment and behavioral abnormalities (NEDLIB) are a disease caused by heterozygous variants in the glutamate ionotropic receptor AMPA type subunit 2 (GRIA2) gene, which manifest as impaired mental development or developmental delay, behavioral abnormalities including autistic characteristics, and language disorders. Currently, only a few mutations in the GRIA2 gene have been discovered.

Methods: A GRIA2 variation was detected in a patient by whole-exome sequencing, and the site was validated by Sanger sequencing from the family.

Results: We report a Chinese case of NEDLIB in a girl with language impairment and developmental delay through whole-exome sequencing (WES). Genetic analysis showed that there was a de novo missense mutation, c.1934T > G (p.Leu645Arg), in the GRIA2 gene (NM_001083619.1), which has never been reported before.

Conclusion: Our case shows the potential diagnostic role of WES in NEDLIB, expands the GRIA2 gene mutation spectrum, and further deepens the understanding of NEDLIB. Deepening the study of the genetic and clinical heterogeneity, treatment, and prognosis of the disease is still our future challenge and focus.

Keywords: GRIA2 gene, case report, neurodevelopmental disorder, language impairment, behavioral abnormalities

INTRODUCTION

Neurodevelopmental disorders with language disorders and behavioral abnormalities (NEDLIB, OMIM#618917) are caused by heterozygous mutations in the glutamate ionotropic receptor AMPA type subunit 2 (GRIA2) gene on chromosome 4q32. The disease can lead to impaired mental development or developmental delay, poor or lack of language ability, abnormal gait, uncoordinated movement, and abnormal behaviors with autism characteristics such as stereotypes, compulsions, and repetitions. Some patients also show clinical features such as seizures and brain atrophy. The disease is onset in infancy, the clinical manifestations are highly...
heterogeneous, and most of them are *de novo* mutations (Salpietro et al., 2019) (Supplementary Table S1).

The glutamate receptor sensitive to α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) is a ligand-activated ion channel that mediates the fast component of excitatory postsynaptic currents in neurons of the central nervous system (Krupp and Feltz, 1995; Kohda et al., 2000). The ion channel is composed of four related subunits: GLURA (*GRIA1*, OMIM*138248), GLURB (*GRIA2*, OMIM*138247), GLURC (*GRIA3*, OMIM*305915), and GLURD (*GRIA4*, OMIM*138246) (Gécz et al., 1999; Armstrong and Gouaux, 2000; Beyer et al., 2008; Allen et al., 2012). The GLURB subunit makes the channel almost impermeable to calcium ions (Ca2+) (Schoepfer et al., 1994; Utz and Verdoorn, 1997).

**CASE DESCRIPTION**

The patient and her parents went to the Medical Genetics Center of Gansu Provincial Maternity and Child Health Hospital for genetic testing. Informed consent was given according to the agreement approved by the Institutional Review Committee. The proband is a 3-year-old female whose parents were healthy and unrelated. The patient had difficulty feeding during the newborn period. Brain MRI suggested brain atrophy in the proband. She could walk independently but was slow in movement. The patient had stereotyped behavior (repeated practice of speaking) and compulsive behavior (bringing her own quilt). She did not speak continuous sentences and did not communicate with others. Her concentration was poor. She was stunted. The child had the ability to paint.

**METHODS**

**Whole-Exome Sequencing**

DNA was obtained from peripheral blood from the patient and her parents. DNA was submitted for trio whole-exome sequencing (trioWES) to Chigene Co., Ltd. Protein-coding exome enrichment was performed using xGen Exome Research Panel v2.0 (IDT, Iowa, United States) that consists of 429,826 individually synthesized and quality-controlled probes, which targets the 39 Mb protein-coding region (19,396 genes) of the human genome and covers 51 Mb of end-to-end tiled probe space. High-throughput sequencing was performed using an MGISEQ-T7 series sequencer, and not less than 99% of the target sequence was sequenced. The sequencing process was performed by Chigene (Beijing) Translational Medical Research Center Co., Ltd.

**Bioinformatics Analysis**

Raw data were processed using fastp for adapter removal and low-quality read filtering. The paired-end reads were performed using a Burrows–Wheeler Aligner (BWA) to the Ensemble GRCh37/
hg19 reference genome. Base quality score recalibration together with SNP and short indel calling was conducted using GATK. According to the sequence depth and variant quality, SNPs and Indels were screened so that high-quality and reliable variants were obtained. The online system independently developed by Chigene (www.chigene.org) was used to annotate database-based minor allele frequencies (MAFs) and ACMG practice guideline–based pathogenicity of every yielded gene variant. The system also provided a series of software packages for conservative analysis and protein product structure prediction. The databases for MAF annotation include 1,000 genomes, dbsNP, ESP, ExAC, and the Chigene in-house MAF database. Provean, Sift, Polypen2_hdiv, Polypen2_hvar, Mutationtaster, M-Cap, and Revel software packages were used to predict

![Pattern diagram of the GRIA2 gene structure, protein domain, protein function, and transmembrane domain and protein sequence conserved analysis.](image-url)
protein product structure variation. As a prioritized pathogenicity annotation to the ACMG guideline (Richards et al., 2015), OMIM, HGMD, and ClinVar databases were used as conferences of pathogenicity of every variant. To predict functional change of variants on the splicing sites, MaxEntScan, dbscSNV, and GTAG software packages were used.

**In silico Analysis**

Gene structure and protein domain model diagrams were performed using Illustrator for Biological Sequences v1.0 (IBS) (Liu et al., 2015). Pfam was used for protein domain prediction (Mistry et al., 2021). Protein morphology and sequence characteristics were drawn using Protter (Omasits et al., 2014). The protein 3D pictures were performed using chimeraX (Pettersen et al., 2021).

**RESULTS**

In this study, a heterozygous missense mutation in the GRIA2 gene c.1934T > G (p.Leu645Arg) was detected in the proband. The mutation was de novo, and the parents were wild-type (Figure 1; Supplementary Table S1). According to ACMG guidelines, this variant was rated as likely to be pathogenic (PS2+PM1+PM2+PP3). The GRIA2 gene (NM_001083619.1) contains 16 exons; part of exon 1 and exons 2–15 are involved in gene coding (Figure 2A). GRIA2 is a transmembrane protein with three main domains: ANF_recepter (green), Lig-chan-Glu_bd (red), and Lig_chan (blue). The three transmembrane (orange diamond) areas are all on Lig_chan. So far, most of the reported missense mutations have been concentrated in the Lig_chan domain. The mutation site Leu645Arg in this study was also in this region (Figure 2B). As shown in the transmembrane protein pattern diagram, the Lig_chan (blue) domain of GRIA2 protein (NP_001077088.2) is transmembrane three times. The Leu645Arg site (arrow) in this case is located in the second transmembrane region. Both the ANF_recepter (green) and Lig_chan-Glu_bd (red) domains are located in the extracellular region (Figure 2C). In the GRIA2 protein sequence alignment of 7 species (human, Norway rat, chimpanzee, house mouse, cattle, chicken, and tropical clawed frog), position 645Leu is located in the conserved sequence (Figure 2D). In the 3D structure of wild-type GRIA2 protein, 645Leu and 641Leu form a hydrogen bond (Figures 3A,B). In the 3D structure of the mutant GRIA2 protein, Leu at position 645 became Arg (645Arg), which formed two hydrogen bonds with 641Leu (Figures 3C,D).

**DISCUSSION AND CONCLUSION**

We report a female patient with neurodevelopmental disorders with language impairment and behavioral abnormalities (NEDLIB), presenting with delayed language development and stereotyped and compulsive behaviors. This is caused by a de novo missense mutation in exon 12 of the GRIA2 gene, which has not been reported previously.

Ionic glutamate receptors (iGluRs) are ligand-gated ion channels activated by the glutamate neurotransmitter (Palmada and Centelles, 1998). iGluRs mediate most of the excitatory synaptic transmission in the central nervous system and play a key role in synaptic plasticity, which is especially important for learning and memory (Murphy-Royal et al., 2017).
Gene mutations in iGluR subunits can cause developmental delay (DD), intellectual disability (ID), and autism spectrum disorders (ASDs) and other related neurodevelopmental disorders (NDDs) (Olde Loohuis et al., 2015; Moretto et al., 2018; Edfawy et al., 2019; Wilding and Huettner, 2020). According to ligand binding characteristics and sequence similarity, iGluRs are divided into 4 subtypes: AMPA receptor, alginate receptor, NMDA receptor, and delta receptor. α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPA Rs) are assembled from the four subunits of Glu1-4, and the most common form in the forebrain is Glu1/Glu2 heterotetramer (Herguedas et al., 2019).

Recent studies have shown that new heterozygous mutations in the GRIA2 gene were found in 28 nonrelated neurodevelopmental abnormalities with language disorders and behavioral abnormalities, including 15 missense variants, 2 splice site variants, 1 nonsense variant, 1 in-frame deletion, and 2 frameshift mutations. These mutations occur in the entire gene. In this case, we discovered a de novo missense variant in the GRIA2 gene, which can lead to NEDLIB (OMIM: #138247). It is also reported that the nonsense mutation of p. Glu508Ter in the GRIA2 gene leads to the occurrence of childhood onset schizophrenia (COS) (Alkelai et al., 2021) (Supplementary Table S1). So far, 16 missense variants of the GRIA2 gene have been reported in 20 patients, including the p. Leu645Arg discovered this time. The phenotypes of patients with missense variants of the GRIA2 gene are shown in Table 1. All patients have developmental delay and language impairment. A considerable number of patients have ASD and abnormal behaviors. Some patients have seizures. Conservation analysis of the amino acid sequence shows that p. Leu645Arg is in a conservative sequence. Including the p. Leu645Arg variant, 12 missense variants are concentrated in the Lig_chan domain. This domain is the transmembrane region of the GRIA2 gene-encoding protein, which forms three transmembranes, and the p.Leu645Arg site is located in the second transmembrane region. It could be seen that the Lig_chan domain may be the hotspot mutation region of the GRIA2 gene.

Taken together, our research has expanded the GRIA2 gene mutation spectrum, indicating that the detection and diagnosis of NEDLIB through WES is feasible and effective.

### TABLE 1 | Clinical phenotypes of patients with missense variation of the GRIA2 gene reported to date.

| Patient | Variant | Age | Gender | DD | ID | ASD | Speech impairment | Abnormal behavior | Seizures | Brain imaging | Study |
|---------|---------|-----|--------|-----|----|-----|------------------|------------------|----------|-------------|-------|
| 1       | c.140G > A; p.Gly47Glu | 13 years | F | Yes | Yes | Yes | Yes | Yes | No | N/A | Normal | Sajipietro et al. (2019) |
| 2       | c.345C > G; p.Ser115Arg | N/A | N/A | N/A | N/A | Yes | N/A | N/A | N/A | N/A | Normal | Sajipietro et al. (2019) |
| 3       | c.905A > G; p.Asp302Gly | 10 years | M | Yes | Yes | Yes | Yes | No | No | Normal | Sajipietro et al. (2019) |
| 4       | c.1582C > A; p.Pro528Thr | 9 years | M | Yes | Yes | Yes | Yes | No | No | Normal | Sajipietro et al. (2019) |
| 5       | c.1819C > G; p.Arg607Gly | 11 years | F | Yes | Yes | Yes | Yes | Yes | Abnormal | Abnormal | Sajipietro et al. (2019) |
| 6       | c.1825G > A; p.Gly609Arg | 19 years | F | Yes | Yes | Yes | No | Yes | Yes | Abnormal | Sajipietro et al. (2019) |
| 7       | c.1831G > A; p.Asp611Asn | 19 years | M | Yes | Yes | Yes | Yes | No | No | Normal | Sajipietro et al. (2019) |
| 8       | c.1915G > T; p.Ala639Ser | 3 ms | M | Yes | N/A | N/A | N/A | No | Abnormal | Normal | Sajipietro et al. (2019) |
| 9       | c.1915G > T; p.Ala639Ser | 5 ms | F | Yes | N/A | N/A | N/A | No | Abnormal | Normal | Sajipietro et al. (2019) |
| 10      | c.1932C > A; p.Phe644Leu | 8 years | F | Yes | Yes | Yes | Yes | No | No | Normal | Sajipietro et al. (2019) |
| 11      | c.1934T > G; p.Lys645Arg | 3 years | F | Yes | N/A | No | Yes | No | Abnormal | Abnormal | Sajipietro et al. (2019) |
| 12      | c.1937C > A; p.Thr646Asn | 3 years | F | Yes | N/A | No | Yes | No | Abnormal | Abnormal | Sajipietro et al. (2019) |
| 13      | c.1939G > C; p.Val647Leu | 9 years | M | Yes | Yes | N/A | Yes | No | Yes | Normal | Sajipietro et al. (2019) |
| 14      | c.1939G > C; p.Val647Leu | 5 years | M | Yes | Yes | Yes | Yes | No | No | Abnormal | Sajipietro et al. (2019) |
| 15      | c.1939G > C; p.Val647Leu | 3 years | M | Yes | Yes | N/A | Yes | No | Yes | Abnormal | Sajipietro et al. (2019) |
| 16      | c.1939G > C; p.Val647Leu | 5 years | M | Yes | Yes | N/A | Yes | No | Yes | No | Sajipietro et al. (2019) |
| 17      | c.2363G > T; p.Trp788Leu | 3.5 years | M | Yes | Yes | N/A | Yes | No | Yes | Abnormal | Sajipietro et al. (2019) |
| 18      | c.2375G > T; p.Gly792Val | 31 years | F | Yes | Yes | Yes | Yes | No | N/A | Abnormal | Current study |
| 19      | c.2420C > T; p.Ala647Val | 3.6 years | F | Yes | Yes | Yes | Yes | Yes | Normal | Sajipietro et al. (2019) |
| 20      | c.2435A > G; p.Asn812Ser | 3 years | M | Yes | Yes | Yes | Yes | Yes | No | No | Sajipietro et al. (2019) |

DD, developmental delay; ID, intellectual disability; ASD, autism spectrum disorder; ys, years; ms, months.
DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the Review Board of the Institutional Review Committee of Gansu Provincial Maternity and Child Health Hospital. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the individual(s) and the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS
BZ and LH designed the study. CZ, LZ, and WG performed the genetic analysis and bioinformatics evaluations. BZ and LW drafted the article. XC, QZ, and SH conducted the clinical evaluations. ZW and XF collected clinical data and follow-up. All authors analyzed the data and approved the final article.

FUNDING
The work was supported by the Technology Innovation Base and Talent Program of Gansu Provincial Department of Science: the clinical application of high-throughput sequencing technology in molecular diagnosis of genetic diseases and the major research project of Gansu Provincial Maternity and Child Health Hospital.

ACKNOWLEDGMENTS
We are grateful to the patient and her family for participation in the study.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.794766/full#supplementary-material

REFERENCES
Alkelai, A., Shohat, S., Greenbaum, L., Schechter, T., Draiman, B., Chitrit-Raveh, E., et al. (2021). Expansion of the GRIA2 Phenylic Representation: A Novel De Novo Loss of Function Mutation in a Case with Childhood Onset Schizophrenia. J. Hum. Genet. 66 (3), 339–343. doi:10.1038/s10038-020-00846-1
Allen, N. J., Bennett, M. L., Foo, L. C., Wang, G. X., Chakraborty, C., Smith, S. J., et al. (2012). Astrocyte Glycans 4 and 6 Promote Formation of Excitatory Synapses via GluA1 AMPA Receptors. Nature 486 (7403), 410–414. doi:10.1038/nature11059
Armstrong, N., and Gouaux, E. (2000). Mechanisms for Activation and Antagonism of an AMPA-Sensitive Glutamate Receptor. Neuron 28 (1), 165–181. doi:10.1016/s0896-6273(00)00994-5
Beyer, B., Deleuze, C., Letts, V. A., Mahaffey, C. L., Boumil, R. M., Lew, T. A., et al. (2019). Architecture of the Heteromeric GluA1/2 AMPA Receptor in Complex Transporters in the Brain: Regulating Neurotransmitter Homeostasis and Synaptic Behaviours in Gprasp2 Mutant Mice. Front. Biosci. –718. doi:10.2741/a314
Edfawy, M., Guedes, J. R., Pereira, M. I., Laranjo, M., Carvalho, M. J., Gao, X., et al. (2018). Glutamatergic Transporters in the Brain: Regulating Neurotransmitter Homeostasis and Synaptic Transmission. J. Neurosci. Res. 95 (11), 2140–2151. doi:10.1002/jnr.24029
Ishii, T., Moriyoshi, K., Sugihara, H., Sakurada, K., Kadotani, H., Yokoi, M., et al. (1993). Molecular Characterization of the Family of the N-Methyl-D-Aspartate Receptor Subunits. J. Biol. Chem. 268 (4), 2836–2843. doi:10.1016/s0021-9258(18)33849-7
Kohda, K., Wang, Y., and Yuzuki, M. (2000). Mutation of a Glutamate Receptor Motif Reveals its Role in Gating and 82 Receptor Channel Properties. Nat. Neurosci. 3 (4), 315–322. doi:10.1038/73877
Murray-Royal, C., Dupuis, J., Groc, L., and Oliet, S. H. R. (2017). Astroglial Glutamate Transporters in the Brain: Regulating Neurotransmitter Homeostasis and Synaptic Transmission. J. Neurosci. Res. 95 (1), 70–82. doi:10.1002/jnr.24029
Pettersen, E. F., Goddard, T. D., Huang, C. C., Meng, E. C., Couch, G. S., Croll, T. L., et al. (2021). UCSF ChimeraX: Structure Visualization for Researchers, Educators, and Developers. Protein Sci. 30 (1), 70–82. doi:10.1002/pro.3943
Richards, S., Aziz, N., Aziz, N., Vale, S., Bick, D., Das, S., et al. (2015). Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics

AUTHOR CONTRIBUTIONS
BZ and LH designed the study. CZ, LZ, and WG performed the genetic analysis and bioinformatics evaluations. BZ and LW drafted the article. XC, QZ, and SH conducted the clinical evaluations. ZW and XF collected clinical data and follow-up. All authors analyzed the data and approved the final article.

FUNDING
The work was supported by the Technology Innovation Base and Talent Program of Gansu Provincial Department of Science: the clinical application of high-throughput sequencing technology in molecular diagnosis of genetic diseases and the major research project of Gansu Provincial Maternity and Child Health Hospital.

ACKNOWLEDGMENTS
We are grateful to the patient and her family for participation in the study.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.794766/full#supplementary-material
Salpietro, V., Dixon, C. L., Dixon, C. L., Guo, H., Bello, O. D., Vandrovoca, J., et al. (2019). AMPA Receptor GluA2 Subunit Defects Are a Cause of Neurodevelopmental Disorders. *Nat. Commun.* 10 (1), 3094. doi:10.1038/s41467-019-10910-w

Satterstrom, F. K., Kosmicki, J. A., Wang, J., Breon, M. S., De Rubeis, S., An, J. Y., et al. (2020). Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. *Cell.* 180 (3), 568–584. e23. doi:10.1016/j.cell.2019.12.036

Schoepfer, R., Monyer, H., Sommer, B., Wisden, W., Sprengel, R., Kuner, T., et al. (1994). Molecular Biology of Glutamate Receptors. *Prog. Neurobiol.* 42 (2), 353–357. doi:10.1016/0301-0082(94)90076-0

Tong, G., Shepherd, D., and Jahr, C. E. (1995). Synaptic Desensitization of NMDA Receptors by Calcineurin. *Science* 267 (5203), 1510–1512. doi:10.1126/science.7878472

Utz, A. L., and Verdoorn, T. A. (1997). Recombinant AMPA Receptors with Low Ca2+ Permeability Increase Intracellular Ca2+ in HEK 293 Cells. *Neuroreport* 8 (8), 1975–1980. doi:10.1097/00001756-199705260-00036

Wilding, T. J., and Huettner, J. E. (2020). Cadmium Activates AMPA and NMDA Receptors with M3 helix Cysteine Substitutions. *J. Gen. Physiol.* 152 (7), e201912537. doi:10.1085/jgp.201912537

Yamakura, T., and Shimoji, K. (1999). Subunit- and Site-Specific Pharmacology of the NMDA Receptor Channel. *Prog. Neurobiol.* 59 (3), 279–298. doi:10.1016/s0301-0082(99)00007-6

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhou, Zhang, Zheng, Wang, Chen, Feng, Zhang, Hao, Wei, Gu and Hui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.